Cellectis S.A.
| NASDAQ: CLLS | Healthcare / Biotechnology / France |
| 2.88 | +0.0300 | +1.05% | Vol 67.71K | 1Y Perf 28.96% |
| Dec 6th, 2023 16:00 DELAYED |
| BID | 2.86 | ASK | 2.94 | ||
| Open | 2.90 | Previous Close | 2.85 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 12.17 | Analyst Rating | Strong Buy 1.33 | |
| Potential % | 322.57 | Finscreener Ranking | ★★★+ 51.67 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★ 41.38 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★+ 46.95 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 62.30 | Earnings Rating | Neutral | |
| Market Cap | 131.55M | Earnings Date | 6th Nov 2023 | |
| Alpha | -0.03 | Standard Deviation | 0.34 | |
| Beta | 3.09 |
Today's Price Range 2.852.97 | 52W Range 0.96284.04 | 5 Year PE Ratio Range -5.20-10.80 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -6.56% | ||
| 1 Month | 3.26% | ||
| 3 Months | 58.33% | ||
| 6 Months | 39.71% | ||
| 1 Year | 28.96% | ||
| 3 Years | -90.32% | ||
| 5 Years | -86.19% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -19.62 | |||
ROE last 12 Months | -61.69 | |||
ROA (5Y Avg) | -15.10 | |||
ROA last 12 Months | -33.15 | |||
ROC (5Y Avg) | -23.38 | |||
ROC last 12 Months | -36.32 | |||
Return on invested Capital Q | -11.47 | |||
Return on invested Capital Y | -5.33 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.10 | ||||
| 0.78 | ||||
| 46.95 | ||||
| 266.40 | ||||
| -1.20 | ||||
| -2.33 | ||||
| 0.72 | ||||
| 3.00 | ||||
| 106.69M | ||||
| Forward PE | -2.70 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.50 | ||||
| 2.60 | ||||
| 0.36 | ||||
| 0.71 | ||||
| -31.90 | ||||
| Leverage Ratio | 1.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 128.10 | ||||
| -792.00 | ||||
| -792.00 | ||||
| -445.20 | ||||
| -86.60 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.26M | ||||
| 0.07 | ||||
| 78.83 | ||||
| 15.09 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.36 | -0.31 | 13.89 |
| Q02 2023 | -0.38 | -0.14 | 63.16 |
| Q01 2023 | -0.30 | -0.58 | -93.33 |
| Q04 2022 | -0.75 | -0.57 | 24.00 |
| Q03 2022 | -0.58 | -0.63 | -8.62 |
| Q02 2022 | -0.73 | -0.42 | 42.47 |
| Q01 2022 | -0.62 | -0.70 | -12.90 |
| Q04 2021 | -1.05 | -0.55 | 47.62 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -0.48 | -2.13 | Negative |
| 12/2023 QR | -0.47 | -38.24 | Negative |
| 12/2023 FY | -1.53 | 6.13 | Positive |
| 12/2024 FY | -1.06 | 3.64 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | -0.36 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 67.71K |
| Shares Outstanding | 45.68K |
| Shares Float | 36.39M |
| Trades Count | 570 |
| Dollar Volume | 196.58K |
| Avg. Volume | 852.65K |
| Avg. Weekly Volume | 165.44K |
| Avg. Monthly Volume | 515.73K |
| Avg. Quarterly Volume | 1.88M |
Cellectis S.A. (NASDAQ: CLLS) stock closed at 2.85 per share at the end of the most recent trading day (a -0.7% change compared to the prior day closing price) with a volume of 104.68K shares and market capitalization of 131.54M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 264 people. Cellectis S.A. CEO is Andre Choulika.
The one-year performance of Cellectis S.A. stock is 28.96%, while year-to-date (YTD) performance is 35.71%. CLLS stock has a five-year performance of -86.19%. Its 52-week range is between 0.962777 and 4.04, which gives CLLS stock a 52-week price range ratio of 62.30%
Cellectis S.A. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 0.78, a price-to-sale (PS) ratio of 46.95, a price to cashflow ratio of 266.40, a PEG ratio of -, a ROA of -33.15%, a ROC of -36.32% and a ROE of -61.69%. The company’s profit margin is -86.60%, its EBITDA margin is -792.00%, and its revenue ttm is $3.26 Million , which makes it $0.07 revenue per share.
Of the last four earnings reports from Cellectis S.A., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.36 for the next earnings report. Cellectis S.A.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Cellectis S.A. is Strong Buy (1.33), with a target price of $12.17, which is +322.57% compared to the current price. The earnings rating for Cellectis S.A. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cellectis S.A. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cellectis S.A. has a Buy technical analysis rating based on Technical Indicators (ADX : 24.23, ATR14 : 0.23, CCI20 : 24.57, Chaikin Money Flow : 0.15, MACD : 0.28, Money Flow Index : 67.26, ROC : 8.78, RSI : 57.32, STOCH (14,3) : 46.67, STOCH RSI : 0.00, UO : 56.44, Williams %R : -53.33), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cellectis S.A. in the last 12-months were:
Cellectis S.A.
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. The company reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.
CEO: Andre Choulika
Telephone: +33 181691600
Address: 8 rue de la Croix Jarry, Paris 75013, , FR
Number of employees: 264
TipRanks News for CLLS
Wed, 22 Nov 2023 12:22 GMT Cellectis price target lowered to $10 from $12 at Citi
- TipRanks. All rights reserved.Tue, 07 Nov 2023 17:31 GMT Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS), Agenus (AGEN) and OrthoPediatrics (KIDS)
- TipRanks. All rights reserved.Mon, 07 Aug 2023 04:30 GMT Analysts Conflicted on These Healthcare Names: Cellectis SA (CLLS), Globus Medical (GMED) and Blueprint Medicines (BPMC)
- TipRanks. All rights reserved.
